Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £33.34B | 67.6x | -1.37 | 46,323.08 | -9.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £28.90B | -900x | -11.15 | 47,711.72 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £11.39B | 21.2x | 1.53 | 16,976.23 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £8B | 109.5x | -1.51 | 3,588.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £5.97B | -46.1x | 3.15 | 8,454.96 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.79B | 16.2x | 0.12 | 3,311.96 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.08B | 137.3x | -1.79 | 1,644 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.8% Upside | Upgrade to Pro+ | |
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £455.01M | -3x | 0.03 | 430 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.6% Upside | Upgrade to Pro+ | |
PureTech Health PLC | London | Healthcare | Biotechnology & Medical Research | £400.79M | -7.1x | 0.08 | 168 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £293.74M | -5.6x | -0.09 | 6.10 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £190.52M | 23.5x | -7.06 | 3,575 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.3% Upside | Upgrade to Pro+ | |
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £180.90M | -4.6x | -1.23 | 170 | -11.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £171.10M | -1.6x | -0.13 | 396.18 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £169.70M | -5.4x | -0.15 | 46.25 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £156.86M | -15.9x | 0.31 | 1,200 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44% Upside | Upgrade to Pro+ | |
Hvivo | London | Healthcare | Biotechnology & Medical Research | £150.29M | 8.4x | 0.02 | 22 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £147.53M | -3.6x | -0.08 | 1,186.98 | -39.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £126.03M | -0.8x | -0.19 | 149.55 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £103.65M | -16.4x | -3.71 | 11.50 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £100.65M | -27.7x | -0.9 | 33.25 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £81.44M | -0.9x | -0.02 | 307.71 | -25.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £80.91M | -241.7x | 1.47 | 18.60 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £77.56M | -3.2x | -0.12 | 59.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £58.37M | -62.9x | 24.08 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £48.40M | 154x | -1.93 | 95.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £42.14M | -1.1x | 0.02 | 59 | 18% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £40.36M | -1x | -0.02 | 323.66 | 126.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £39.02M | -11.4x | -1.28 | 17.35 | 8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £36M | -11.1x | -0.79 | 7.14 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sareum | London | Healthcare | Biotechnology & Medical Research | £32.62M | -6.2x | -1.03 | 26.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |